CRISPR patent win bolsters Editas Medicine (NASDAQ: EDIT) IP estate
Filing Impact
Filing Sentiment
Form Type
8-K
Rhea-AI Filing Summary
Editas Medicine announced that the U.S. Patent and Trademark Office has reaffirmed the Patent Trial and Appeal Board’s prior decision favoring the Broad Institute in a key CRISPR/Cas9 patent interference covering gene editing in human cells. This is the PTAB’s third favorable decision confirming Broad as first to invent CRISPR/Cas9 use in eukaryotic cells.
The CRISPR/Cas9 patents at issue are exclusively licensed to Editas for developing and commercializing CRISPR/Cas9-based medicines, underpinning its gene editing pipeline. Other in-licensed Broad, Harvard, MIT and collaborator patents, including CRISPR/Cas12a rights, are not involved in this interference and remain unaffected.
Management highlighted this outcome as reinforcing confidence in the company’s intellectual property as it advances in vivo gene editing programs, including EDIT-401, an experimental one-time therapy that has achieved greater than 90 percent mean LDL cholesterol reduction in non-human primates. CVC parties retain the right to appeal the decision to the Federal Circuit.
Positive
- CRISPR/Cas9 interference win: The U.S. Patent and Trademark Office reaffirmed a PTAB decision in favor of the Broad Institute on CRISPR/Cas9 patents in human cells, which are exclusively licensed to Editas for medicines, reinforcing the company’s foundational intellectual property.
- Strong preclinical signal for EDIT-401: The company highlighted EDIT-401, an experimental in vivo gene editing therapy that has achieved greater than 90 percent mean LDL cholesterol reduction in non-human primates, supporting the potential of its pipeline.
Negative
- None.
Insights
Favorable CRISPR/Cas9 ruling strengthens Editas’s core patent base.
The decision confirms, for a third time, that Broad was first to invent CRISPR/Cas9 editing in eukaryotic cells, including human cells. Because Editas holds exclusive rights to these patents for medicines, this ruling directly supports the legal foundation of its gene editing platform.
The company notes that other CRISPR/Cas9 and CRISPR/Cas12a patents it licenses from Broad, Harvard, MIT and collaborators are not part of this interference and are unaffected. This suggests a broad, multi-layered IP estate across technologies and geographies, which can be important for long-term competitive positioning.
Uncertainty remains because the CVC parties can still appeal to the Court of Appeals for the Federal Circuit. Investors may focus on future disclosures about any appeal, as well as progress of programs like EDIT-401, which showed greater than 90% mean LDL cholesterol reduction in non-human primates.
8-K Event Classification
3 items: 7.01, 8.01, 9.01
3 items
Item 7.01
Regulation FD Disclosure
Disclosure
Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.
Item 8.01
Other Events
Other
Voluntary disclosure of events the company deems important to shareholders but not covered by other items.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
_________________________________________________________________________________________
FORM 8-K
_________________________________________________________________________________________
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): March 26, 2026
_________________________________________________________________________________________
(Exact Name of Registrant as Specified in its Charter)
_________________________________________________________________________________________
| (State or Other Jurisdiction of Incorporation) | (Commission File Number) | (IRS Employer Identification No.) | ||||||
| (Address of Principal Executive Offices) | (Zip Code) | |||||||
Registrant’s telephone number, including area code: (617 ) 401-9000
(Former Name or Former Address, if Changed Since Last Report)
__________________________________________________________________________________________________
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |||||
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |||||
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |||||
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) | |||||
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||||||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company o
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o
Item 7.01 Regulation FD Disclosure.
On March 27, 2026, Editas Medicine, Inc. (the “Company”) issued a press release titled “Editas Medicine Announces U.S. Patent and Trademark Office Reaffirms its Prior Decision in Favor of the Broad Institute in CRISPR/Cas9 Interference.” A copy of the press release is being furnished as Exhibit 99.1 to this Current Report on Form 8-K.
The information contained in Item 7.01 in this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed “Filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.
Item 8.01 Other Events.
On March 26, 2026, the U.S. Patent and Trademark Office reaffirmed the Patent Trial and Appeal Board’s (“PTAB’s”) previous decision favoring the Broad Institute in the U.S. patent interference involving specific patents for CRISPR/Cas9 editing in human cells between the University of California, the University of Vienna, and Emmanuelle Charpentier (collectively, “CVC”) and the Broad Institute, Massachusetts Institute of Technology, and Harvard University. The patent interference was on remand from the U.S. Court of Appeals for the Federal Circuit (“CAFC”) following the CAFC’s May 2025 decision to affirm-in-part and vacate-in-part the PTAB’s prior decision. CVC retains the right to appeal the decision to the CAFC.
Item 9.01 Financial Statements and Exhibits.
(d)Exhibits
| Exhibit No. | Description | |||||||
| 99.1 | Press release issued by the Company on March 27, 2026* | |||||||
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) | |||||||
*This exhibit shall be deemed to be furnished and not filed.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| EDITAS MEDICINE, INC. | ||||||||
Date: March 27, 2026 | By: | /s/ Amy Parison | ||||||
| Amy Parison | ||||||||
| Chief Financial Officer | ||||||||
Exhibit 99.1
Editas Medicine Announces U.S. Patent and Trademark Office Reaffirms its Prior Decision in Favor of the Broad Institute in CRISPR/Cas9 Interference
CAMBRIDGE, Mass., March 27, 2026 – Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today announced that the U.S. Patent and Trademark Office reaffirmed the Patent Trial and Appeal Board’s (PTAB’s) previous decision favoring the Broad Institute in the U.S. patent interference involving specific patents for CRISPR/Cas9 editing in human cells between the University of California, the University of Vienna, and Emmanuelle Charpentier (collectively, CVC) and the Broad Institute, Massachusetts Institute of Technology (MIT), and Harvard University (collectively, Broad).
The patent interference was on remand from the U.S. Court of Appeals for the Federal Circuit (CAFC) following the CAFC’s May 2025 decision to affirm-in-part and vacate-in-part the PTAB’s prior decision. This action by the PTAB is its third favorable decision determining that Broad was the first to invent the use of CRISPR/Cas9 for gene editing in eukaryotic cells, including human cells. CVC retains the right to appeal the decision to the CAFC.
“We are pleased with decision reaffirming Broad’s inventorship priority for CRISPR/Cas9 gene editing,” said Gilmore O’Neill, M.B., M.M.Sc., President and Chief Executive Officer, Editas Medicine. “This outcome reinforces our confidence in our intellectual property as we continue to leverage the power of in vivo gene editing to create transformative medicines for people living with serious diseases. This includes the development of EDIT-401, an experimental, potential best-in-class, one-time therapy that has achieved an unprecedented greater than 90 percent mean LDL cholesterol reduction in non-human primates.”
The CRISPR/Cas9 patents at issue are exclusively licensed to Editas Medicine for the development and commercialization of CRISPR/Cas9-based medicines.
Other in-licensed patents from the Broad Institute, Harvard University, MIT, and other institutions covering CRISPR/Cas9, as well as those in-licensed patents from the Broad Institute and collaborators covering CRISPR/Cas12a, are not at issue in the interference and are unaffected by this decision.
Editas Medicine’s foundational intellectual property includes issued patents covering fundamental aspects of both CRISPR/Cas12a and CRISPR/Cas9 gene editing in all human cells. Additionally, the Company holds a wide range of fundamental intellectual property directed to all the components of its gene editing platform including product-enabling and product-specific intellectual property covering the use of CRISPR/Cas12a and CRISPR/Cas9 for gene editing of human cells in the United States, Australia, Europe, Japan, China, and other jurisdictions.
About Editas Medicine
As a pioneering gene editing company, Editas Medicine is focused on translating the power and potential of CRISPR genome editing systems into a robust pipeline of in vivo medicines for people living with serious diseases around the world. Editas Medicine aims to discover, develop, manufacture, and commercialize transformative, durable, precision in vivo gene editing medicines for a broad class of diseases. Editas Medicine is the exclusive licensee of Broad Institute’s Cas12a patent estate and Broad Institute and Harvard University’s Cas9 patent estates for human medicines. For the latest information and scientific presentations, please visit www.editasmedicine.com.
Forward-Looking Statements
This press release contains forward-looking statements and information within the meaning of The Private Securities Litigation Reform Act of 1995. The words ‘‘anticipate,’’ ‘‘believe,’’ ‘‘continue,’’ ‘‘could,’’ ‘‘estimate,’’ ‘‘expect,’’ ‘‘intend,’’ ‘‘may,’’ ‘‘plan,’’ ‘‘potential,’’ ‘‘predict,’’ ‘‘project,’’ ‘‘target,’’ ‘‘should,’’ ‘‘would,’’ and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. The Company may not actually achieve the plans, intentions, or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various important factors, including: uncertainties inherent with litigation, including patent interference proceedings; and uncertainties inherent in the initiation, timing, progress, and results of preclinical studies and clinical trials. These and other risks are described in greater detail under the caption “Risk Factors” included in the Company’s most recent Annual Report on Form 10-K, which is on file with the Securities and Exchange Commission, as updated by the Company’s subsequent filings with the Securities and Exchange Commission, and in other filings that the Company may make with the Securities and Exchange Commission in the future. Any forward-looking statements contained in this press release speak only as of the date hereof, and the Company expressly disclaims any obligation to update any forward-looking statements, whether because of new information, future events or otherwise.
This press release contains hyperlinks to information that is not deemed to be incorporated by reference in this press release.
###
Investor and Media Contacts:
ir@editasmed.com
media@editasmed.com
FAQ
What did the latest USPTO decision mean for Editas Medicine (EDIT)?
The USPTO reaffirmed a PTAB decision favoring the Broad Institute in a CRISPR/Cas9 patent interference. Because Editas exclusively licenses these patents for medicines, the ruling supports the company’s core gene editing intellectual property position in human cells.
Which CRISPR/Cas9 patents are involved in Editas Medicine’s recent 8-K?
The decision concerns specific CRISPR/Cas9 patents for editing in human cells disputed between CVC and Broad, MIT, and Harvard. The PTAB again backed Broad’s inventorship priority, and these patents are exclusively licensed to Editas for developing and commercializing CRISPR/Cas9-based medicines.
Are Editas Medicine’s other CRISPR patents affected by this interference ruling?
No, the company states that other in-licensed CRISPR/Cas9 and CRISPR/Cas12a patents from the Broad Institute, Harvard, MIT, and collaborators are not at issue in the interference. Those additional patent rights remain unaffected by this decision, maintaining Editas’s broader IP coverage.
Can the losing CVC parties still challenge the CRISPR/Cas9 decision mentioned by Editas (EDIT)?
Yes. Editas notes that the CVC parties retain the right to appeal the USPTO’s reaffirmed decision to the U.S. Court of Appeals for the Federal Circuit. That means the interference proceeding may continue through further appellate review before reaching a final conclusion.
How does the decision relate to Editas Medicine’s EDIT-401 program?
Editas highlights the decision as supporting confidence in its IP while it develops in vivo gene editing programs such as EDIT-401. The company reports EDIT-401 achieved greater than 90 percent mean LDL cholesterol reduction in non-human primates, suggesting strong preclinical activity for this experimental therapy.
What is Editas Medicine’s overall CRISPR intellectual property position?
Editas describes foundational IP with issued patents covering CRISPR/Cas9 and CRISPR/Cas12a gene editing in all human cells. It also holds product-enabling and product-specific patents across the United States, Australia, Europe, Japan, China, and other jurisdictions, supporting its in vivo gene editing pipeline.
Filing Exhibits & Attachments
5 documentsPress Releases
Editas Medicine Inc
NASDAQ:EDIT
EDIT Rankings
EDIT Latest News
EDIT Latest SEC Filings
Mar 9, 2026
[10-K] Editas Medicine, Inc. Files Annual Report
EDIT Stock Data
218.25M
97.61M
Biotechnology
Biological Products, (no Diagnostic Substances)
United States
CAMBRIDGE